Biotech Values

[drbio45]

The 250 mg dose of MC-1 had a 14.0% reduction in the primary endpoint composite of death, non-fatal myocardial infarction (peak CK-MB greater than or equal to 50ng/ml), and non-fatal stroke versus placebo (p equals 0.312).

Since you follow the space and are aware of the alxn results you also know that the peak ck-mb of 100ng/ml is the most appropriate endpoint and medicure's data shows that it reduces the risk of MI and death when that marker is used.

The phase 2 only had 900 patients and they thought by lowering the endpoint to 50ng/ml they would see more events but it created noise.

but then again I am sure you knew that